U
345.09
2.63 (0.77%)
| Previous Close | 342.46 |
| Open | 348.10 |
| Volume | 114,286 |
| Avg. Volume (3M) | 517,930 |
| Market Cap | 15,353,245,696 |
| Price / Earnings (TTM) | 15.87 |
| Price / Earnings (Forward) | 12.99 |
| Price / Sales | 6.43 |
| Price / Book | 2.66 |
| 52 Weeks Range | |
| Earnings Date | 30 Oct 2024 - 4 Nov 2024 |
| Profit Margin | 40.31% |
| Operating Margin (TTM) | 54.51% |
| Diluted EPS (TTM) | 22.75 |
| Quarterly Revenue Growth (YOY) | 22.90% |
| Quarterly Earnings Growth (YOY) | 15.50% |
| Total Debt/Equity (MRQ) | 6.56% |
| Current Ratio (MRQ) | 4.58 |
| Operating Cash Flow (TTM) | 1.14 B |
| Levered Free Cash Flow (TTM) | 710.09 M |
| Return on Assets (TTM) | 11.89% |
| Return on Equity (TTM) | 18.81% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | United Therapeutics Corporation | Bullish | Bullish |
AIStockmoo Score
-0.2
| Analyst Consensus | 1.5 |
| Insider Activity | -2.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.0 |
| Average | -0.20 |
|
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Core |
| % Held by Insiders | 1.84% |
| % Held by Institutions | 99.97% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 600.00 (Oppenheimer, 73.87%) | Buy |
| Median | 400.00 (15.91%) | |
| Low | 302.00 (Goldman Sachs, -12.49%) | Hold |
| Average | 420.86 (21.96%) | |
| Total | 6 Buy, 1 Hold | |
| Avg. Price @ Call | 372.44 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| UBS | 08 Jan 2025 | 475.00 (37.65%) | Buy | 366.61 |
| Goldman Sachs | 01 Nov 2024 | 302.00 (-12.49%) | Hold | 374.02 |
| Argus Research | 31 Oct 2024 | 400.00 (15.91%) | Buy | 373.97 |
| HC Wainwright & Co. | 31 Oct 2024 | 425.00 (23.16%) | Buy | 373.97 |
| Ladenburg Thalmann | 31 Oct 2024 | 344.00 (-0.31%) | Buy | 373.97 |
| Oppenheimer | 31 Oct 2024 | 600.00 (73.87%) | Buy | 373.97 |
| TD Cowen | 21 Oct 2024 | 400.00 (15.91%) | Buy | 370.60 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BENKOWITZ MICHAEL | - | 355.39 | -10,000 | -3,553,900 |
| MAHON PAUL A | - | 360.22 | -7,700 | -2,773,694 |
| Aggregate Net Quantity | -17,700 | |||
| Aggregate Net Value ($) | -6,327,594 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 357.81 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BENKOWITZ MICHAEL | Officer | 06 Jan 2025 | Automatic sell (-) | 10,000 | 355.39 | 3,553,900 |
| BENKOWITZ MICHAEL | Officer | 06 Jan 2025 | Option execute | 10,000 | - | - |
| MAHON PAUL A | Officer | 02 Jan 2025 | Automatic sell (-) | 7,700 | 360.22 | 2,773,694 |
| MAHON PAUL A | Officer | 02 Jan 2025 | Option execute | 7,700 | - | - |
| Date | Type | Details |
|---|---|---|
| 06 Jan 2025 | Announcement | United Therapeutics Corporation to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
| 17 Dec 2024 | Announcement | United Therapeutics Announces Successful World’s First UKidney Transplant |
| 05 Nov 2024 | Announcement | United Therapeutics Corporation to Present at the UBS Global Healthcare Conference |
| 30 Oct 2024 | Announcement | United Therapeutics Corporation Reports Third Quarter 2024 Financial Results |
| 23 Oct 2024 | Announcement | United Therapeutics Corporation Announces the 500th Lung Transplant Utilizing its Centralized Ex Vivo Lung Perfusion Service |
| 23 Oct 2024 | Announcement | United Therapeutics Corporation to Report Third Quarter 2024 Financial Results Before the Market Opens on Wednesday, October 30, 2024 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |